Items Tagged ‘Gemzar’

May 3, 2012

Threshold Pharmaceuticals’ TH-302

By Mystery User

Before AACR, the company announced top-line results from a Phase IIb trial of Lilly’s Gemzar (gemcitabine)  TH-302, a hypoxia-activated prodrug, in front-line pancreatic cancer showing a statistically significant 2.0 month improvement in PFS with the combination (5.6 months vs. 3.6 months for Gemzar alone, p=0.005, HR 061). TheMitesh Borad, MD, an oncologist from the […]

View full entry

Tags: AACR Newsletter, Dr. Mitesh Borad, Gemzar, pancreatic cancer

Contact Us · Privacy Policy